Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Thrombomodulin alfa - Asahi Kasei Pharma Corp

Drug Profile

Thrombomodulin alfa - Asahi Kasei Pharma Corp

Alternative Names: ART-123; AT 908; Human recombinant thrombomodulin - Asahi Kasei Pharma Corp; Recombinant human soluble thrombomodulin - Asahi Kasei Pharma Corp; Recombinant thrombomodulin alfa - Asahi Kasei Pharma Corp; Recombinant thrombomodulin alpha - Asahi Kasei Pharma Corp; Recomodulin; Recomodulin® anticoagulant intravenous infusion 12800; rhs-TM - Asahi Kasei Pharma Corp; Thrombomodulin alpha - Asahi Kasei Pharma Corp; TMD-123

Latest Information Update: 25 Feb 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Asahi Kasei; Asahi Kasei Pharma Corp
  • Developer Asahi Kasei; Asahi Kasei Pharma America Corp; Asahi Kasei Pharma Corp
  • Class Anti-inflammatories; Anticoagulants; Antifibrotics; Antithrombotics; Peptides; Platelet membrane glycoproteins; Recombinant proteins
  • Mechanism of Action Protein C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Disseminated intravascular coagulation
  • Phase II Peripheral nervous system diseases
  • Discontinued Deep vein thrombosis; Idiopathic pulmonary fibrosis

Most Recent Events

  • 24 Feb 2022 Veloxis Pharmaceuticals plans a phase I trial for Colorectal cancer (Combination therapy, Metastatic disease) and Peripheral neuropathies (Chemotherapy-induced) in February 2022 (IV) (NCT05251727)
  • 02 Feb 2022 Veloxis Pharmaceuticals withdrew a phase II trial prior to enrolment due to change in study design in Peripheral nervous system diseases (Prevention) (IV) (NCT04492436)
  • 16 Mar 2021 Phase III development is ongoing in Disseminated intravascular coagulation in sepsis (severe sepsis with coagulopathy) outside Japan (IV) (Asahi Kasei Pharma Corp website, March 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top